Clinical Trials

Rosiglitazone has been evaluated in numerous Phase 1 through Phase 4 clinical trials, including drug interaction studies and assessments in healthy volunteers. These trials investigate conditions ranging from metabolic disorders, Alzheimer's disease, hepatitis C, cystic fibrosis, and erectile dysfunction to neoplasms like non-small cell lung cancer, thyroid cancer, and renal cell carcinoma. Sponsored by both academic institutions and pharmaceutical companies, overall trial statuses include completed, active, recruiting, terminated, suspended, and withdrawn protocols.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04114136 RECRUITING
Melanoma; NSCLC; Hepatocellular Carcinoma; Urothelial Cancer; Gastric Adenocarcinoma; HNSCC; Esophageal Adenocarcinoma; Microsatellite Instability-High Solid Malignant Tumor
Dan Zandberg
 2020-09-14 PHASE2
NCT01019356 COMPLETED
Polycystic Ovary Syndrome
Jean-Patrice Baillargeon
 2006-08
NCT02694874 COMPLETED
Malaria
Centro de Investigacao em Saude de Manhica
 2016-02
NCT03309319 UNKNOWN
Pituitary Tumor
Zhaoyun Zhang
 2016-10-16
NCT01287598 COMPLETED
Neoplasms
Bayer
 2011-08-02 PHASE1
NCT02737709 Terminated
Non-small Cell Lung Cancer
Sun Yat-sen University
 2016-03 Phase 2
NCT00640224 COMPLETED
Polycystic Ovary Syndrome
Silva Arslanian
 2005-03 PHASE4
NCT01174056 COMPLETED
Lung Inflammation
Washington University School of Medicine
 2011-07 EARLY_PHASE1
NCT00240604 UNKNOWN
Glucose Intolerance
Hadassah Medical Organization
 2005-04 PHASE3
NCT00933309 COMPLETED
Breast Cancer
M.D. Anderson Cancer Center
 2009-07 PHASE1
NCT00577590 COMPLETED
Diabetes Mellitus, Type II
Washington University School of Medicine
 2003-10
NCT01100619 COMPLETED
Papillary Thyroid Cancer; Follicular Thyroid Cancer; Huerthle Cell Thyroid Cancer; Renal Cell Carcinoma
Exelixis
 2010-04 PHASE1
NCT00607945 COMPLETED
Type 2 Diabetes Mellitus
Ohio State University
 2008-01 PHASE1
NCT00953498 COMPLETED
Type 2 Diabetes
Centre Hospitalier Universitaire Dijon
 2007-10 PHASE4
NCT01209143 COMPLETED
Solid Cancers
Genentech, Inc.
 2010-11 PHASE1
NCT00242593 UNKNOWN
Mild Cognitive Impairment
University of Washington
 2006-06 PHASE2
NCT00964106 COMPLETED
Drug Interactions
GlaxoSmithKline
 2009-08-26 PHASE1
NCT01402076 Completed
Healthy Volunteers
Vanda Pharmaceuticals
 2011-08 Phase 1
NCT01402076 COMPLETED
Healthy Volunteers
Vanda Pharmaceuticals
 2011-08 PHASE1
NCT00831129 COMPLETED
Pre-diabetes
University of Chicago
 2006-09 PHASE2; PHASE3
NCT00081328 COMPLETED
Diabetes Mellitus, Type II
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
 2004-05 PHASE3
NCT00337350 COMPLETED
Schizophrenia
Massachusetts General Hospital
 2003-09 PHASE4
NCT00618072 COMPLETED
Hyperinsulinemia; Insulin Resistance; Obesity
New York Medical College
 2008-01 PHASE2
NCT01406704 TERMINATED
NASH (Non-alcoholic Steato-hepatitis)
Seoul St. Mary's Hospital
 2004-01 PHASE4
NCT00612066 TERMINATED
Cushing's Disease
Jonsson Comprehensive Cancer Center
 2007-04 PHASE2
NCT00616642 TERMINATED
Brain and Central Nervous System Tumors
Jonsson Comprehensive Cancer Center
 2006-10 PHASE2
NCT00879970 TERMINATED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2009-05 PHASE4
NCT01453049 TERMINATED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2010-04 PHASE3
NCT00679939 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2008-04-21 PHASE4
NCT00252499 TERMINATED
Fatty Liver; Insulin Resistance
US Department of Veterans Affairs
 2005-10
NCT01574820 COMPLETED
Prediabetes; Coronary Artery Disease; Insulin Resistance; Glucose Intolerance
National Cheng-Kung University Hospital
 2006-11 PHASE3
NCT00130286 COMPLETED
HIV-Associated Lipodystrophy Syndrome; Insulin Resistance; HIV Infections; Metabolic Syndrome X; Body Weight Changes
Weill Medical College of Cornell University
 2005-03 PHASE1; PHASE2
NCT01017666 COMPLETED
Healthy
Biogen
 2009-11-01 PHASE1
NCT00098852 UNKNOWN
Head and Neck Cancer
University of California, San Francisco
 2004-10 PHASE2
NCT00819910 TERMINATED
Hypertriglyceridemia in Type 4 Hyperlipidemia; Non Diabetic Subjects With Normoglycemia
Ahmad Slim
 2008-09 PHASE4
NCT01376063 COMPLETED
Healthy Adult Subjects
Kyntra Bio
 2010-03 PHASE1
NCT01415128 COMPLETED
Erectile Dysfunction
VIVUS LLC
 2010-04 PHASE1
NCT01100619 Completed
Papillary Thyroid Cancer|Follicular Thyroid Cancer|Huerthle Cell Thyroid Cancer|Renal Cell Carcinoma
Exelixis
 2010-04 Phase 1
NCT01415128 Completed
Erectile Dysfunction
VIVUS LLC
 2010-04 Phase 1
NCT01150981 COMPLETED
Metabolic Syndrome; Insulin Resistance
University of Massachusetts, Worcester
 2006-11 PHASE2
NCT01376063 Completed
Healthy Adult Subjects
FibroGen
 2010-03 Phase 1
NCT01060566 COMPLETED
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
 2010-02 PHASE1
NCT01088594 COMPLETED
Type 2 Diabetes Mellitus
Solvay Pharmaceuticals
 2010-02 PHASE1
NCT00614874 COMPLETED
Asthma
Creighton University
 2008-12 PHASE2
NCT00116922 COMPLETED
Impaired Glucose Tolerance; Diabetes
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
 2004-06 PHASE3
NCT00207402 COMPLETED
Hepatitis C
Brooke Army Medical Center
 2005-10 PHASE4
NCT01332071 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2009-11-24 PHASE1
NCT00242619 COMPLETED
Depression; Bipolar Disorder; Insulin Resistance
Stanford University
 2007-07
NCT00738023 COMPLETED
Type 2 Diabetes; Hypertension
Emory University
 2004-03 PHASE4
NCT00143624 COMPLETED
Atherosclerosis; HIV Infections
University of British Columbia
 2003-06
NCT00680745 COMPLETED
Type 2 Diabetes
AstraZeneca
 2008-04 PHASE3
NCT00609362 COMPLETED
Change in Bone Mineral Density; Change in Bone Marrow Fat Content
University of Aarhus
 2008-01 PHASE2
NCT00884533 WITHDRAWN
Alzheimer's Disease
GlaxoSmithKline
 2009-06 PHASE1
NCT00699036 UNKNOWN
Nonalcoholic Steatohepatitis; Nonalcoholic Fatty Liver Disease
Brooke Army Medical Center
 2007-04 PHASE2
NCT00490568 TERMINATED
Alzheimer's Disease
GlaxoSmithKline
 2007-08-08 PHASE3
NCT00486187 COMPLETED
Type 2 Diabetes Mellitus
Dr. Milan Gupta
 2006-04
NCT00811356 TERMINATED
Malaria
GlaxoSmithKline
 2008-12-11 PHASE1
NCT00348140 COMPLETED
Alzheimer's Disease
GlaxoSmithKline
 2006-07-12 PHASE3
NCT00550420 TERMINATED
Alzheimer's Disease
GlaxoSmithKline
 2007-10-01 PHASE3
NCT00381238 COMPLETED
Alzheimer's Disease
GlaxoSmithKline
 2006-06-20 PHASE2
NCT01872780 COMPLETED
Healthy
Inje University
 2008-08 PHASE1
NCT00348309 COMPLETED
Alzheimer's Disease
GlaxoSmithKline
 2006-07-06
NCT00437970 WITHDRAWN
Diabetes Mellitus, Type 2
Menzies School of Health Research
 2008-04 PHASE4
NCT00733174 UNKNOWN
Impaired Glucose Tolerance
Denver Research Institute
 2004-03 PHASE4
NCT00367744 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2006-07 PHASE2
NCT00324675 COMPLETED
Type 2 Diabetes; Overt Diabetic Nephropathy
Technische Universität Dresden
 2006-08
NCT00379769 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2001-04 PHASE3
NCT00733785 COMPLETED
Alzheimer's Disease
GlaxoSmithKline
 2008-08-13 PHASE1
NCT00166803 SUSPENDED
Diabetes Mellitus, Atherosclerosis
National Taiwan University Hospital
 2005-06
NCT00367055 COMPLETED
Type 2 Diabetes Mellitus
GlaxoSmithKline
 2004-10 PHASE4
NCT00370305 COMPLETED
Metabolic Syndrome; Impaired Glucose Tolerance
Charite University, Berlin, Germany
 2004-05 PHASE2
NCT00785213 COMPLETED
Healthy
Mutual Pharmaceutical Company, Inc.
 2008-09 PHASE1
NCT00551564 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2007-07-31 PHASE1
NCT00428090 COMPLETED
Alzheimer's Disease
GlaxoSmithKline
 2007-02-27 PHASE3
NCT00688207 COMPLETED
Alzheimer's Disease
GlaxoSmithKline
 2008-04 PHASE1
NCT00186537 COMPLETED
Insulin Resistance; Hypertriglyceridemia
Stanford University
 2003-09
NCT00194896 COMPLETED
Type 2 Diabetes Mellitus
University of Washington
 2000-02
NCT00413335 COMPLETED
Obesity; Impaired Glucose Tolerance; Type 2 Diabetes Mellitus
Yale University
 2005-11
NCT00692510 COMPLETED
Metabolism; Alzheimer's Disease
AstraZeneca
 2007-11 PHASE1
NCT00116831 COMPLETED
Atherosclerosis
GlaxoSmithKline
 2005-01 PHASE3
NCT00265148 COMPLETED
Alzheimer's Disease
GlaxoSmithKline
 2004-05-18 PHASE2
NCT00135330 COMPLETED
Diabetes Mellitus, Type 2
AstraZeneca
 2005-10 PHASE3
NCT00405015 COMPLETED
Ischemia-Reperfusion Injury; The Metabolic Syndrome
Radboud University Medical Center
 2007-04 PHASE2
NCT00032487 COMPLETED
Type 2 Diabetes Mellitus
VA Office of Research and Development
 2000-12-01 PHASE3
NCT00121953 WITHDRAWN
Endometriosis
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
 2005-07 PHASE2; PHASE3
NCT00484419 COMPLETED
Type 2 Diabetes; Hyperlipidemia
Daiichi Sankyo
 2007-05 PHASE3
NCT00427154 TERMINATED
Diabetes; Diabetes Mellitus, Type 2
Novo Nordisk A/S
 2007-01-10 PHASE3
NCT00343980 TERMINATED
Diabetes; Diabetes Mellitus, Type 2
Novo Nordisk A/S
 2006-10-10 PHASE3
NCT00348712 TERMINATED
Diabetes; Diabetes Mellitus, Type 2
Novo Nordisk A/S
 2006-10-30 PHASE3
NCT00567593 COMPLETED
Inflammatory Bowel Disease
James Lewis
 2007-10 PHASE4
NCT00452166 TERMINATED
Chronic Kidney Disease; Insulin Resistance
Leiden University Medical Center
 2007-04 PHASE3
NCT00615212 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2008-01-02 PHASE1
NCT00065065 COMPLETED
Ulcerative Colitis; Inflammatory Bowel Disease
James Lewis
 2002-09 PHASE2
NCT00636766 COMPLETED
Carotid Atherosclerosis; Stroke; Type 2 Diabetes; Metabolic Syndrome
Aristotle University Of Thessaloniki
 2005-09
NCT00466713 TERMINATED
Dilated Cardiomyopathy
Stanford University
 2007-03
NCT00361868 TERMINATED
Dyslipidemia; Glucose Metabolism Disorder
Solvay Pharmaceuticals
 2006-06 PHASE3
NCT00343395 TERMINATED
Coronary Artery Disease
Intermountain Health Care, Inc.
 2006-06 PHASE4
NCT00399711 COMPLETED
Diabetes; Diabetes Mellitus, Type 2
Novo Nordisk A/S
 2006-11 PHASE3
NCT00318656 COMPLETED
Non-Insulin-Dependent Diabetes Mellitus
GlaxoSmithKline
 2005-11 PHASE4
NCT00295633 COMPLETED
Diabetes Mellitus, Type 2
AstraZeneca
 2006-03 PHASE3
NCT00350779 COMPLETED
Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
 2006-06-12 PHASE3
NCT00511823 COMPLETED
Nausea and Vomiting, Chemotherapy-Induced
GlaxoSmithKline
 2007-07-23 PHASE1
NCT00402909 COMPLETED
Type 2 Diabetes
Novartis Pharmaceuticals
 2006-11 PHASE4
NCT00333151 COMPLETED
Diabetes; Diabetes Mellitus, Type 2
Novo Nordisk A/S
 2006-05 PHASE3
NCT00369174 COMPLETED
Oral Leukoplakia
National Cancer Institute (NCI)
 2006-06 PHASE2
NCT00571506 COMPLETED
Diabetes Mellitus, Type 2; Vascular Diseases
University of Arkansas
 2004-05 PHASE4
NCT00121966 COMPLETED
Type 2 Diabetes Mellitus
Odense University Hospital
 2003-01 PHASE4
NCT00169832 COMPLETED
Diabetes; Coronary Artery Bypass Grafting
Laval University
 2003-06 PHASE3
NCT00465296 TERMINATED
Metabolic Syndrome
Medstar Health Research Institute
 2006-01 PHASE3
NCT00334568 TERMINATED
Alzheimer's Disease
GlaxoSmithKline
 2004-12 PHASE2
NCT00297063 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2006-01-11 PHASE3
NCT00468897 COMPLETED
Alzheimer's Disease
GlaxoSmithKline
 2007-03-21 PHASE1
NCT01577095 COMPLETED
Type 2 Diabetes Mellitus With Features of Insulin Resistance
China Medical University Hospital
 2006-04 PHASE2
NCT00318422 COMPLETED
Diabetes; Diabetes Mellitus, Type 2
Novo Nordisk A/S
 2006-05 PHASE3
NCT00138619 COMPLETED
Diabetes Mellitus, Type 2
Novartis
 2004-11 PHASE3
NCT00424762 COMPLETED
Diabetes Mellitus, Type 2
University of Texas Southwestern Medical Center
 2005-02 PHASE4
NCT00432679 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2006-05-24 PHASE3
NCT00541775 COMPLETED
Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
 2006-06 PHASE3
NCT00746174 COMPLETED
Insulin Sensitivity
University of Texas Southwestern Medical Center
 2004-02 PHASE4
NCT00178841 COMPLETED
Cutaneous T-cell Lymphoma; Mycosis Fungoides; Sezary Syndrome
Vanderbilt University
 2005-06 PHASE2
NCT00675740 COMPLETED
Impaired Glucose Tolerance
University of Leipzig
 2004-01 PHASE4
NCT00373178 COMPLETED
Type 2 Diabetes Mellitus
Aristotle University Of Thessaloniki
 2005-01 PHASE4
NCT00379600 COMPLETED
Arthritis, Rheumatoid
GlaxoSmithKline
 2004-11 PHASE2
NCT00362726 COMPLETED
HIV Infections
Bristol-Myers Squibb
 2006-09 PHASE1
NCT00285805 COMPLETED
Insulin Resistance
Radboud University Medical Center
 2006-02
NCT00364221 COMPLETED
Metabolic Syndrome; Insulin Resistance
University of Colorado, Denver
 2004-11 PHASE4
NCT00318630 COMPLETED
Asthma
GlaxoSmithKline
 2005-07-22 PHASE1
NCT00279045 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2000-01-03 PHASE3
NCT00115661 TERMINATED
Endometriosis
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
 2005-07 PHASE2
NCT00084578 WITHDRAWN
Bladder Cancer
Fox Chase Cancer Center
 2004-03
NCT00004180 COMPLETED
Sarcoma
Dana-Farber Cancer Institute
 1999-10 PHASE2
NCT01045590 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2003-12 PHASE4
NCT00015691 COMPLETED
HIV Infections; Lipodystrophy; Hyperinsulinemia
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00241605 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2003-06-25 PHASE4
NCT00123643 COMPLETED
Type 2 Diabetes Mellitus
St. Paul Heart Clinic
 2003-05 PHASE4
NCT00149383 COMPLETED
Falciparum Malaria
Mahidol University
 2004-12 PHASE1; PHASE2
NCT00422955 COMPLETED
Neuropathy, Diabetic
GlaxoSmithKline
 2003-11 PHASE3
NCT00225225 TERMINATED
Diabetes Mellitus, Type 2
Stanford University
 2002-10
NCT00099918 COMPLETED
Diabetes Mellitus, Type 2
Novartis Pharmaceuticals
 2004-05 PHASE3
NCT00231387 COMPLETED
Non-insulin-dependent Diabetes Mellitus
GlaxoSmithKline
 2002-09 PHASE3
NCT04148183 COMPLETED
Insulin Resistance
J JESUS VENEGAS, MD
 2004-01-01 PHASE2; PHASE3
NCT00499707 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2003-10-08 PHASE3
NCT00067951 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2003-10-17 PHASE3
NCT00069836 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2003-10 PHASE3
NCT00306644 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2002-05 PHASE4
NCT00672919 COMPLETED
Diabetes Mellitus
Takeda
 2003-11 PHASE4
NCT00329225 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2002-09 PHASE4
NCT00331487 COMPLETED
Diabetes Mellitus
Takeda
 2000-09 PHASE3
NCT00182052 COMPLETED
Adenocarcinoma of the Prostate; Prostate Cancer
Massachusetts General Hospital
 2000-09 PHASE3
NCT00197132 COMPLETED
Insulin Resistance
GlaxoSmithKline
 2002-10 PHASE3
NCT00044460 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2002-05 PHASE4
NCT00501020 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2001-06-05 PHASE4
NCT00333723 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2000-07-28 PHASE4
NCT02526615 COMPLETED
Insulin Sensitivity; Type 2 Diabetes
Turku University Hospital
 2000-10 PHASE4
NCT00304993 COMPLETED
Metabolic Syndrome X; Insulin Resistance
Foundation Research, Florida
 2001-01 PHASE4
NCT00140647 COMPLETED
Atherosclerosis; Impaired Glucose Tolerance; Isolated Impaired Fasting Glucose; Cardiovascular Disease
Gerstein, Hertzel, MD
 2001-07 PHASE3
NCT00358124 COMPLETED
Type 2 Diabetes Mellitus
Sanofi
 2001-01 PHASE4
NCT00309660 UNKNOWN
Ulcerative Colitis
Herlev Hospital
 2005-11 PHASE1; PHASE2
NCT00225355 TERMINATED
Angina Pectoris; Metabolic Syndrome X
University of Glasgow
 2006-02 PHASE4
NCT00290394 COMPLETED
Diabetes Mellitus, Type 2
Baskent University
 2004-03 PHASE4
NCT00492700 COMPLETED
Non Alcoholic Steatohepatitis
Association pour la Recherche sur les Maladies Hépatiques Virales
 2003-01 PHASE2
NCT00193648 COMPLETED
Focal Glomerulosclerosis
Northwell Health
 2005-07 PHASE1
NCT00274495 TERMINATED
Chronic Hepatitis C Infection; Fatty Liver
Beth Israel Medical Center
 2006-01 PHASE4
NCT00018382 COMPLETED
Alzheimer Disease
US Department of Veterans Affairs
 1999-10 PHASE2
NCT00094796 COMPLETED
Diabetes Mellitus, Type II; Insulin Resistance
National Heart, Lung, and Blood Institute (NHLBI)
 2004-10-20 PHASE2
NCT00516880 UNKNOWN
Chronic Disease; Kidney Diseases; Cardiovascular Diseases
Hospital Authority, Hong Kong
 2006-03
NCT00110851 COMPLETED
Type 2 Diabetes Mellitus
Wellstat Therapeutics
 2005-04 PHASE2
NCT00025753 COMPLETED
HIV Infections; Insulin Resistance
National Center for Research Resources (NCRR)
NCT00443170 COMPLETED
Healthy Subjects; Anaemia
GlaxoSmithKline
 2006-11 PHASE1
NCT00123227 UNKNOWN
Diabetes Mellitus, Type 2; Vascular Diseases; Hypertension
Royal Brompton & Harefield NHS Foundation Trust
 2002-10 PHASE3
NCT00225342 WITHDRAWN
Angina Pectoris; Diabetes Mellitus, Type 2
University of Glasgow
 PHASE4
NCT00440375 COMPLETED
Type 2 Diabetes Mellitus; Obesity; Menopause
Baskent University
 2005-06 PHASE4
NCT00039663 COMPLETED
HIV Infections
National Institutes of Health Clinical Center (CC)
 2002-05 PHASE1
NCT00095654 COMPLETED
Impaired Glucose Tolerance; Cardiovascular Disease; Glucose Metabolism Disorders
Gerstein, Hertzel, MD
 2001-07 PHASE3
NCT00150410 COMPLETED
Diabetes Mellitus
Pfizer
 2003-01 PHASE3
NCT00409097 UNKNOWN
Critical Illness; Multiple Organ Failure
Amsterdam UMC, location VUmc
 2006-04 PHASE3
NCT00483392 COMPLETED
Insulin Resistance
University Medical Centre Ljubljana
NCT00549874 COMPLETED
Type 2 Diabetes
University of Michigan
 2002-02
NCT00203632 TERMINATED
Diabetes Mellitus
University of Calgary
 2003-09 PHASE3
NCT00064727 COMPLETED
Congestive Heart Failure
National Heart, Lung, and Blood Institute (NHLBI)
 2003-07-09 PHASE2
NCT00372086 COMPLETED
Type 1 Diabetes; Puberty: >Tanner 2 Breast Development or Testis >4ml
The University of New South Wales
 2003-08 PHASE4
NCT00349427 COMPLETED
Type 2 Diabetes Mellitus; Diabetes Mellitus, Type 2
GlaxoSmithKline
 2005-10 PHASE3
NCT00522470 COMPLETED
Type 2 Diabetes Mellitus; Obesity
Baskent University
 PHASE4
NCT00500955 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2000-04 PHASE3
NCT00169923 WITHDRAWN
Chronic Kidney Disease; Inflammation
Leiden University Medical Center
 2007-04 PHASE2; PHASE3
NCT00015626 COMPLETED
Insulin Resistance; Diabetes Mellitus
National Center for Research Resources (NCRR)
 PHASE2
NCT00300911 COMPLETED
Diabetes Mellitus, Type 2
Baskent University
 2005-12 PHASE4
NCT00154011 COMPLETED
Healthy Subjects
Technische Universität Dresden
 2005-09
NCT00523913 COMPLETED
Diabetes Mellitus, Type 2
GlaxoSmithKline
 2005-11 PHASE3
NCT00264251 COMPLETED
HIV Infections; Insulin Resistance; Obesity
St. Luke's-Roosevelt Hospital Center
 2005-07
NCT00549263 WITHDRAWN
Healthy Subjects
GlaxoSmithKline
 2008-02 PHASE1
NCT00306696 COMPLETED
Diabetes Mellitus
GlaxoSmithKline
 2002-10 PHASE4
NCT00116792 UNKNOWN
Coronary Artery Disease; Diabetes Mellitus
Gold, Herman K., MD
 2004-03 PHASE2; PHASE3
NCT00314561 COMPLETED
Metabolic Syndrome
Korea University Anam Hospital
 2006-05 PHASE4
NCT00309309 COMPLETED
Kidney Transplant
Mario Negri Institute for Pharmacological Research
 2005-04 PHASE2
NCT00282945 TERMINATED
Type 2 Diabetes Mellitus
Pfizer
 2006-01
NCT00306176 COMPLETED
Type II Diabetes Mellitus
Aristotle University Of Thessaloniki
 2005-01 PHASE4
NCT00006493 COMPLETED
HIV Infections; Hyperlipidemia
National Center for Research Resources (NCRR)
 PHASE2
NCT00489229 COMPLETED
Diabetes; Impaired Glucose Tolerance
Universiti Sains Malaysia
 2002-10 PHASE3
NCT00285142 COMPLETED
Healthy
University Hospital, Montpellier
 2004-06
NCT00232362 WITHDRAWN
Type 2 Diabetes Mellitus
Texas Tech University Health Sciences Center
 2007-06 PHASE1
NCT00119496 COMPLETED
Asthma
University of Glasgow
 2005-07 PHASE2; PHASE3

(data from https://clinicaltrials.gov, updated on 2026-06-23)

Check the Rosiglitazone (BRL 49653) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Rosiglitazone functions as a selective ligand that binds to the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-gamma), thereby altering target gene expression to increase insulin sensitivity and promote terminal adipocyte differentiation. This alteration in nuclear transcription reduces circulating blood glucose and lipid concentrations, establishing its therapeutic efficacy in metabolic disorders while also influencing cell survival pathways relevant to clinical trials evaluating non-small cell lung cancer and other neoplasms.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.